ESPE Yearbook of Paediatric Endocrinology

Brief Summary: This prospective follow-up cohort study investigated bone mineral density in transgender individuals who had initiated GnRH analogue treatment before age 18 followed by sex hormone treatment for at least 9 years. At a median age 28.2 years, after using testosterone for a median 11.9 years (IQR 10.2-13.8), transmasculine individuals had mean z-scores close to 0 at the lumbar spine, total hip and femoral neck, similar to z-scores at the start of GnRH analogue trea...